Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
First Claim
Patent Images
1. A composition for preventing one or more cardiac channelopathies, irregularities, or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject consisting of:
- a therapeutically effective amount of the active agent or the drug, wherein the active agent or drug causes one or more cardiac channelopathies, irregularities, or alterations in cardiac patterns; and
an amount of a lysophosphatidylglycerol in the form of empty liposomes adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug, wherein the lysophosphatidylglycerol includes at least one of a lysophosphatidylcholine, lauroyl-lysophosphatidylcholine, myristoyl-lysophosphatidylcholine, palmitoyl-lysophosphatidylcholine, stearoyl-lysophosphatidylcholine, arachidoyl-lysophosphatidylcholine, oleoyl-lysophosphatidylcholine, linoleoyl-lysophosphatidylcholine, linolenoyl-lysophosphatidylcholine or erucoyl-lysophosphatidylcholine.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug.
80 Citations
18 Claims
-
1. A composition for preventing one or more cardiac channelopathies, irregularities, or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject consisting of:
-
a therapeutically effective amount of the active agent or the drug, wherein the active agent or drug causes one or more cardiac channelopathies, irregularities, or alterations in cardiac patterns; and an amount of a lysophosphatidylglycerol in the form of empty liposomes adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug, wherein the lysophosphatidylglycerol includes at least one of a lysophosphatidylcholine, lauroyl-lysophosphatidylcholine, myristoyl-lysophosphatidylcholine, palmitoyl-lysophosphatidylcholine, stearoyl-lysophosphatidylcholine, arachidoyl-lysophosphatidylcholine, oleoyl-lysophosphatidylcholine, linoleoyl-lysophosphatidylcholine, linolenoyl-lysophosphatidylcholine or erucoyl-lysophosphatidylcholine. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
-
10. A composition for preventing or treating a diseases with an active agent or drug that causes one or more adverse reactions arising from administration of an active agent or drug in a human that causes at least one of cardiac channelopathies, IKr channel inhibition or QT prolongation consisting of:
-
a therapeutically effective amount of the active agent or the drug, wherein the active agent or drug causes the at least one of cardiac channelopathies, IKr channel inhibition or QT prolongation; and an amount of a lysophosphatidylglycerol with a basic structure; - View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 18)
-
Specification